These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37914638)

  • 1. Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study.
    Cases A; Sánchez EGA; Cadeddu G; Lorenzo MM
    Nefrologia (Engl Ed); 2023; 43(5):562-574. PubMed ID: 37914638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
    Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
    Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: findings from a retrospective real-world study in Italy.
    Minutolo R; Grandaliano G; Di Rienzo P; Snijder R; Degli Esposti L; Perrone V; Todorova L
    J Nephrol; 2023 Mar; 36(2):347-357. PubMed ID: 36370331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan.
    Mishina S; Waratani M; Onozawa S; Okumura H; Ito Y; Yasuda Y
    Nephrology (Carlton); 2023 Aug; 28(8):446-455. PubMed ID: 37161826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study.
    Cases-Amenós A; Martínez-Castelao A; Fort-Ros J; Bonal-Bastons J; Ruiz MP; Vallés-Prats M; Coll-Piera E; Galcerán-Gui JM;
    Nefrologia; 2014; 34(2):189-98. PubMed ID: 24658193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology.
    Cases A; Egocheaga MI; Tranche S; Pallarés V; Ojeda R; Górriz JL; Portolés JM
    Nefrologia (Engl Ed); 2018; 38(1):8-12. PubMed ID: 29128260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
    Minutolo R; Locatelli F; Gallieni M; Bonofiglio R; Fuiano G; Oldrizzi L; Conte G; De Nicola L; Mangione F; Esposito P; Dal Canton A;
    Nephrol Dial Transplant; 2013 Dec; 28(12):3035-45. PubMed ID: 24145459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology].
    Cases A; Egocheaga MI; Tranche S; Pallarés V; Ojeda R; Górriz JL; Portolés JM
    Semergen; 2018; 44(1):37-41. PubMed ID: 29229312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis.
    Escudero-Vilaplana V; Martínez-Nieto C; López-Gómez JM; Vega-Martínez A; Bellón-Cano JM; Sanjurjo-Sáez M
    Int J Clin Pharm; 2013 Jun; 35(3):463-8. PubMed ID: 23595914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
    Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
    BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology].
    Cases A; Egocheaga MI; Tranche S; Pallarés V; Ojeda R; Górriz JL; Portolés JM
    Aten Primaria; 2018 Jan; 50(1):60-64. PubMed ID: 29224999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents.
    Io H; Aizawa M; Funabiki K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():7-13. PubMed ID: 26439537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013.
    Evans M; Suttorp MM; Bellocco R; Hoekstra T; Qureshi AR; Dekker FW; Carrero JJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):628-35. PubMed ID: 26243782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.